Latest news with #March2025
Gizmodo
15 hours ago
- Business
- Gizmodo
Apple Quality at a Lower Price, Amazon Crushes iPad 2025 Prices to a New All-Time Low
Thanks to this discount, the iPad 2025 is almost as affordable as many of the basic tablets offered by rival brands. Apple's reputation for making the best-of-the-best devices is well deserved. iPhones, iPads, Watches and MacBooks set the benchmark by which everything else is measured within their particular markets. The iPad offers the convenience of a tablet with the functionality to get work, creativity and entertainment tasks done. That convenience just became even greater with the new 11-inch iPad that was released in March 2025. Already, Amazon is selling this latest model for a record-low price: the 128GB Wi-Fi model is selling for only $299 which is a 14 percent discount from its $349 list price. See at Amazon This makes the iPad 2025 an even better option if you want to enjoy Apple's best-of-the-best experience without the best-of-the-best price that normally comes with it. The new iPad is powered by the super-fast A16 chip which provides a definite boost of performance to duties, way better than the previous processor. Premium Display, Great UI The 11-inch Liquid Retina display is stunning and it provides vibrant colors and it boasts True Tone technology that balances the screen to the light around you in the room. Not only a nicer thing to look at but also less harsh on eyes during prolonged use. iPadOS is the ideal complement to the hardware and it helps the iPad to be more productive. You can have several apps open at once, type in any text field with Apple Pencil via Scribble Technology and access a massive catalog of apps crafted specifically for the iPad. The Magic Keyboard Folio and Apple Pencil transform this tablet into a powerful tool for note-taking, sketching and typing, with a wonderful keyboard and responsive trackpad for precision control. Connectivity is also a strong area of this 2025 tablet as it comes with fast Wi-Fi 6 for quick file transfers, seamless streaming and live video chats. The USB-C charging point ensures easy charging and porting of peripherals and all-day battery life allows you to use your iPad for work or play without searching for a plug. The camera and video capabilities are quite robust for a tablet (you just can't compare it to an iPhone, but it's definitely among the best tablets in 2025) such as a 12MP Wide rear camera that is 4K video-enabled and a 12MP Center Stage front camera that is well-suited for video calls. Scanning receipts, capturing moments, or participating in a video call, the iPad cameras deliver high-quality shots even if you're a beginner. This is one the best deals on a premium device you'll find this year, make sure you grab yours asap. See at Amazon
Yahoo
2 days ago
- Business
- Yahoo
Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers So should Lantern Pharma (NASDAQ:LTRN) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When Lantern Pharma last reported its March 2025 balance sheet in May 2025, it had zero debt and cash worth US$20m. Importantly, its cash burn was US$19m over the trailing twelve months. Therefore, from March 2025 it had roughly 12 months of cash runway. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for Lantern Pharma Lantern Pharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 40%, which suggests that management are increasing investment in future growth, but not too quickly. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. While Lantern Pharma does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Lantern Pharma's cash burn of US$19m is about 57% of its US$34m market capitalisation. That's high expenditure relative to the value of the entire company, so if it does have to issue shares to fund more growth, that could end up really hurting shareholders returns (through significant dilution). On this analysis of Lantern Pharma's cash burn, we think its cash runway was reassuring, while its cash burn relative to its market cap has us a bit worried. After looking at that range of measures, we think shareholders should be extremely attentive to how the company is using its cash, as the cash burn makes us uncomfortable. On another note, we conducted an in-depth investigation of the company, and identified 6 warning signs for Lantern Pharma (3 make us uncomfortable!) that you should be aware of before investing here. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 days ago
- Business
- Yahoo
Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. But while history lauds those rare successes, those that fail are often forgotten; who remembers So should Lantern Pharma (NASDAQ:LTRN) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. Let's start with an examination of the business' cash, relative to its cash burn. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. When Lantern Pharma last reported its March 2025 balance sheet in May 2025, it had zero debt and cash worth US$20m. Importantly, its cash burn was US$19m over the trailing twelve months. Therefore, from March 2025 it had roughly 12 months of cash runway. While that cash runway isn't too concerning, sensible holders would be peering into the distance, and considering what happens if the company runs out of cash. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for Lantern Pharma Lantern Pharma didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 40%, which suggests that management are increasing investment in future growth, but not too quickly. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. While Lantern Pharma does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. Commonly, a business will sell new shares in itself to raise cash and drive growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Lantern Pharma's cash burn of US$19m is about 57% of its US$34m market capitalisation. That's high expenditure relative to the value of the entire company, so if it does have to issue shares to fund more growth, that could end up really hurting shareholders returns (through significant dilution). On this analysis of Lantern Pharma's cash burn, we think its cash runway was reassuring, while its cash burn relative to its market cap has us a bit worried. After looking at that range of measures, we think shareholders should be extremely attentive to how the company is using its cash, as the cash burn makes us uncomfortable. On another note, we conducted an in-depth investigation of the company, and identified 6 warning signs for Lantern Pharma (3 make us uncomfortable!) that you should be aware of before investing here. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies with significant insider holdings, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CTV News
5 days ago
- Entertainment
- CTV News
Cassie Ventura welcomes third child: reports
Cassie Ventura, seen here at an event on March 31, 2025 in New York City, has welcomed her third child. (via CNN Newsource) Singer Cassie Ventura, who recently testified as a central witness in the federal criminal trial of her ex-boyfriend Sean 'Diddy' Combs, has given birth to her third child, multiple outlets have reported. Ventura and her husband, Alex Fine, welcomed a son. They are also the parents of two young daughters, Frankie and Sunny. CNN has reached out to representatives for the couple for comment. In February, they announced a new addition was joining the family. Earlier this month, Ventura gave nearly 20 hours of often graphic testimony during Combs' trial, speaking about the violence she said she endured at Combs' hands and detailing drug-fueled sexual encounters, known as 'Freak Offs.' Ventura was the third witness to be called and referred to by both the defense and prosecution as an important witness in the case. Combs has pleaded not guilty to charges that include racketeering conspiracy, sex trafficking and transportation to engage in prostitution. If convicted on the most serious counts, he could face up to life in prison. Combs and Ventura's longterm relationship is part of the ongoing criminal case against him. She was identified as 'Victim 1' in the federal indictment against Combs. Ventura first detailed years of disturbing abuse allegations in a civil lawsuit filed against Combs, who she dated on and off between 2007 and 2018, in November 2023. The two settled her claim for $20 million one day after it was filed, according to Ventura's testimony at the trial. On the stand, Ventura said she was treated for mental health problems, including post-traumatic stress disorder, after the relationship ended. Combs has faced dozens of other civil lawsuits in recent months, accusing him of sexual assault. He has denied all the allegations. On the opening day of Combs's trial, the jury was shown graphic video of him physically assaulting Ventura in a California hotel in 2016. During pretrial hearings, the defense unsuccessfully attempted to keep the jury from being able to see the video of the incident during the trial. Prior to Ventura's testimony at trial, Combs' defense team made their best effort to have Ventura seated at the witness stand before the jury entered the courtroom. 'I'm going to ask that victim number one, when she testifies, be already in the jury box when the jury comes in. Only as to her. Only because of her physical condition,' Combs' attorney, Marc Agnifilo, said in court ahead of Ventura's testimony, according to a court-provided transcript of the exchange. 'There is – there is a quality to her walking in front of the jury that I think is easily avoidable.' Judge Arun Subramanian, who is overseeing the case, ultimately denied the request. Outside the court on May 13, Ventura's attorney Douglas Wigdor said: 'The jury is going to judge her based on her testimony – not based on her appearance, hopefully.' After she completed her time on the stand, Ventura issued a statement through her attorney that said in part, 'I hope that my testimony has given strength and a voice to other survivors, and can help others who have suffered to speak up and also heal from the abuse and fear.'
Yahoo
26-05-2025
- Business
- Yahoo
Compared to Estimates, Sunrun (RUN) Q1 Earnings: A Look at Key Metrics
For the quarter ended March 2025, Sunrun (RUN) reported revenue of $504.27 million, up 10.1% over the same period last year. EPS came in at $0.20, compared to -$0.40 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $493.97 million, representing a surprise of +2.09%. The company delivered an EPS surprise of +190.91%, with the consensus EPS estimate being -$0.22. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Sunrun performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Solar Energy Capacity Installed for Subscribers: 375 MW versus the five-analyst average estimate of 176.85 MW. Networked Solar Energy Capacity: 7,721 MW compared to the 8,009.15 MW average estimate based on three analysts. Revenue- Customer agreements and incentives: $402.92 million versus the six-analyst average estimate of $378.92 million. The reported number represents a year-over-year change of +24.8%. Revenue- Solar energy systems and product sales: $101.35 million versus the six-analyst average estimate of $114.44 million. The reported number represents a year-over-year change of -25.1%. Revenue- Solar energy systems: $40.07 million compared to the $57.83 million average estimate based on four analysts. The reported number represents a change of -38.4% year over year. Revenue- Incentives: $21.56 million compared to the $32.02 million average estimate based on four analysts. The reported number represents a change of +14.5% year over year. Revenue- Products: $61.28 million versus $59.26 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -12.7% change. Revenue- Customer agreements: $381.36 million versus $346.90 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +25.4% change. Gross Profit- Solar Energy Systems and Product: $4.55 million versus the four-analyst average estimate of $6.12 million. Gross Profit- Customer Agreements and Incentives: $94.29 million compared to the $56.14 million average estimate based on four analysts. View all Key Company Metrics for Sunrun here>>>Shares of Sunrun have returned -6.9% over the past month versus the Zacks S&P 500 composite's +8.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sunrun Inc. (RUN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
